Aortic stenosis occurs when the opening of the heart’s aortic valve becomes narrowed, restricting the blood flow from the heart to the rest of the body.
Aortic stenosis (AS) is a progressive heart valve disease that leads to the narrowing of the aortic valve opening, restricting blood flow from the heart to the rest of the body.
This condition, if left untreated, can result in heart failure and is associated with a high mortality rate. Traditionally, the only treatment option was open-heart surgery to replace the valve.
However, advancements in medical technology have introduced a less invasive procedure known as Transcatheter Aortic Valve Implantation (TAVI).
Understanding aortic stenosis
Aortic stenosis is most commonly caused by age-related calcification of the valve, but it can also result from congenital defects or rheumatic heart disease.
In Malaysia, the prevalence of heart valve diseases, including AS, is a growing concern due to an ageing population and increasing rates of cardiovascular risk factors such as hypertension and diabetes.
What Is TAVI?
TAVI is a minimally invasive procedure that involves implanting a new aortic valve using a catheter, typically inserted through the femoral artery in the groin.
This approach eliminates the need for open-heart surgery and is particularly beneficial for patients who are at high risk due to age or other medical conditions.
The procedure offers a quicker recovery time and less postoperative pain.
TAVI is performed through small openings, making it a less invasive option for high-risk patients.
A leader in TAVI
Institut Jantung Negara (IJN) has been at the forefront of cardiac care in Malaysia and the Asean region.
In 2009, IJN became the first hospital in Asia to introduce TAVI, setting a precedent for advanced heart care in the region. Since then, IJN has continued to lead in this field, performing many procedures to date.
One of the significant milestones was the successful implantation of the Navitor TAVI device in May 2025, making IJN the first in Malaysia to perform this advanced procedure.
This achievement underscores IJN's commitment to adopting cutting-edge technologies to improve patient outcomes.
Advancements in TAVI Technology
The field of TAVI has seen significant technological advancements. IJN has been instrumental in introducing these innovations to Malaysia.
In 2020, IJN became the first hospital in the Asean region to implant the Myval, an advanced man-made heart valve, in a patient.
These technological advancements have enhanced the precision and safety of TAVI procedures, leading to improved patient outcomes and expanded treatment options for those with aortic stenosis.
The impact on patients
TAVI’s introduction has revolutionised the treatment of aortic stenosis, especially for patients who are not candidates for traditional open-heart surgery.
The minimally invasive nature of the procedure allows for quicker recovery times, reduced risk of complications, and a faster return to normal activities.
Patients who previously had limited treatment options now have access to a life-saving procedure that significantly improves their quality of life.
TAVI has enabled more efficient and precise treatment for aortic stenosis with improved long-term outcomes. Its small profile makes it convenient to treat smaller patients and the elderly population.
Looking ahead
As the field of TAVI continues to evolve, IJN remains committed to advancing heart care through the adoption of innovative technologies and procedures.
The institute's leadership in TAVI not only reflects its dedication to patient care but also positions Malaysia as the regional leader in cardiac care.
Datuk Dr Shaiful Azmi Yahaya is the chief clinical officer and senior consultant cardiologist at Institut Jantung Negara (IJN).
